*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

# ANNOUNCEMENT

# UNAUDITED FINANCIAL RESULTS OF CR PHARMACEUTICAL COMMERCIAL FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026 IN RELATION TO ISSUANCE OF MEDIUM TERM NOTES IN THE PRC

Reference is made to: (i) the announcement dated 1 December 2025 in relation to, among others, the proposed issuance of medium term notes in the PRC by China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) ("**CR Pharmaceutical Commercial**"), a non-wholly-owned subsidiary of the Company; and (ii) the announcement dated 15 December 2025 in relation to, among others, the completion of the issuance of the first tranche of medium term notes for the year of 2025 in the PRC by CR Pharmaceutical Commercial (the "**Announcements**"). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless stated otherwise herein.

In accordance with the relevant rules and regulations in the PRC and in connection with its issuance of medium term notes in the PRC, CR Pharmaceutical Commercial has published its unaudited financial statements for the nine months ended 30 September 2026 on the website of China Money in connection with the medium term notes.

The unaudited financial statements of CR Pharmaceutical Commercial for the nine months ended 30 September 2026 (the "**Unaudited Financial Statements of CR Pharmaceutical Commercial**") are enclosed to this announcement for the Company's shareholders' information only. The Unaudited Financial Statements of CR Pharmaceutical Commercial were prepared in Chinese and have been translated for publication in English and Chinese. In the event of any inconsistency between the two versions, the Chinese version shall prevail. In addition, the Unaudited Financial Statements of CR Pharmaceutical Commercial have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company's auditors, and may require adjustments during the course of auditing. Such financial information is limited to CR Pharmaceutical Commercial only and does not represent or provide a complete view of the operational or financial status of the Group.

**Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

By order of the Board
**China Resources Pharmaceutical Group Limited**
**Mr. Bai Xiaosong**
*Chairman*

PRC, 30 October 2026

*As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.*

# CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED
# CONSOLIDATED BALANCE SHEET
# SEPTEMBER 2026

**Unit: RMB**

| Item | 30 September 2026 | 31 December 2025 | Item | 30 September 2026 | 31 December 2025 |
|---|---|---|---|---|---|
| **Current assets:** | | | **Current liabilities:** | | |
| Monetary fund | 8,275,785,024.00 | 10,257,067,215.35 | Short-term borrowings | 39,640,902,391.10 | 33,455,137,520.39 |
| Notes receivable | 311,112,609.55 | 241,598,060.17 | Notes payable | 19,172,308,933.32 | 20,489,498,505.52 |
| Accounts receivable | 92,208,799,563.12 | 81,953,462,510.56 | Accounts payable | 47,660,202,276.52 | 39,973,927,485.76 |
| Financing receivables | 11,177,529,240.38 | 9,314,180,265.98 | Contract liabilities | 3,163,471,774.97 | 1,567,788,033.34 |
| Prepayment | 4,517,843,764.38 | 3,550,359,009.85 | Staff remuneration payable | 1,150,631,379.68 | 1,095,089,453.36 |
| Other receivables | 5,813,342,391.65 | 5,660,783,137.51 | Taxation payable | 511,819,743.07 | 706,961,740.62 |
| Inventory | 37,542,600,197.34 | 33,397,894,883.62 | Other payables | 7,705,624,703.53 | 7,558,385,842.13 |
| Contract assets | 16,942,895.25 | 36,368,075.40 | Non-current liabilities due within one year | 5,390,560,329.46 | 5,347,902,389.66 |
| Non-current assets due within one year | 471,005,267.73 | – | Other current liabilities | 138,589,869.33 | 116,541,074.19 |
| Other current assets | 1,469,032,483.44 | 1,555,535,755.91 | | | |
| **Total current assets** | **161,803,993,436.84** | **145,967,248,914.35** | **Total current liabilities** | **124,534,111,400.98** | **110,311,232,044.97** |
| **Non-current assets:** | | | **Non-current liabilities:** | | |
| Long-term receivables | 711,433,579.41 | 804,033,995.94 | Long-term borrowings | 3,397,933,095.27 | 6,235,411,075.59 |
| Other equity instruments investments | 2,066,000.00 | 2,066,000.00 | Bonds payable | 11,998,931,679.52 | 7,996,868,303.42 |
| Long-term equity investments | 2,088,324,041.20 | 1,981,171,228.00 | Long-term payables | 168,438,874.67 | 163,142,206.67 |
| Investment properties | 96,117,949.58 | 99,246,587.13 | Long-term employee remuneration payable | 122,131,692.27 | 120,549,334.37 |
| Other non-current financial assets | 23,960,022.62 | 23,960,022.62 | Deferred revenue | 18,533,161.19 | 20,920,263.10 |
| Fixed assets | 3,505,234,081.46 | 3,737,047,170.91 | Estimated liabilities | – | – |
| Right-of-use assets | 749,049,642.64 | 807,820,687.26 | Deferred income tax liabilities | 430,564,298.32 | 247,739,539.83 |
| Construction in progress | 377,761,403.57 | 96,931,766.61 | Lease liabilities | 501,781,647.60 | 508,652,160.77 |
| Intangible assets | 1,835,419,134.28 | 1,934,472,919.85 | **Total non-current liabilities** | **16,638,314,448.84** | **15,293,282,883.75** |
| Goodwill | 9,732,712,191.40 | 9,732,712,191.40 | **Total liabilities** | **141,172,425,849.82** | **125,604,514,928.72** |
| Long-term deferred expenses | 108,113,341.19 | 133,660,255.99 | **Owners' equity (or shareholders' equity):** | | |
| Deferred income tax assets | 1,090,876,343.22 | 863,531,449.51 | Paid-in capital (equity) | 19,646,531,357.61 | 19,646,531,357.61 |
| Other non-current assets | 80,115,168.83 | 59,096,473.50 | Other equity instruments | 6,000,000,000.00 | 6,000,000,000.00 |
| **Total non-current assets** | **20,401,182,899.40** | **20,275,750,748.72** | Capital surplus | 2,385,748,813.11 | 2,366,137,504.91 |
| | | | Other comprehensive income | –34,579,353.52 | –33,858,479.73 |
| | | | Surplus reserves | 1,284,626,198.44 | 1,284,626,198.44 |
| | | | Special reserves | 188,214.12 | 188,214.12 |
| | | | Undistributed profits | 6,026,098,529.30 | 5,692,606,987.57 |
| | | | **Total equity attributable to owners of the parent company** | **35,308,613,759.06** | **34,956,231,782.92** |
| | | | △Minority interests | 5,724,136,727.36 | 5,682,252,951.43 |
| | | | **Total owners' equity** | **41,032,750,486.42** | **40,638,484,734.35** |
| **Total assets** | **182,205,176,336.24** | **166,242,999,663.07** | **Total liabilities and owners' equity** | **182,205,176,336.24** | **166,242,999,663.07** |

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED**
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS**
**JANUARY TO SEPTEMBER 2026**

**Unit: RMB**

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **Operating revenue** | **169,460,437,978.21** | **165,101,152,699.37** |
| **Less: Operating costs** | **158,655,791,233.57** | **154,503,825,507.92** |
| Tax and surcharge | 353,131,574.00 | 345,534,995.04 |
| Selling expenses | 4,366,549,423.50 | 4,163,074,728.30 |
| Management expenses | 1,897,039,951.76 | 1,882,929,895.03 |
| Research and development expenses | 17,171,118.89 | 40,996,237.74 |
| Finance costs | 1,010,483,670.17 | 1,131,687,829.19 |
| Including: Interest expenses | 977,675,416.99 | 1,125,029,685.80 |
| Interest income | 24,976,107.10 | 51,696,369.02 |
| Add: Other revenue | 34,898,470.95 | 32,665,654.42 |
| Gain from investment | –13,993,436.72 | –27,243,853.78 |
| Including: Gains from investment in associates and joint ventures | 104,611,444.75 | 106,098,658.24 |
| Gains from changes in fair values | – | –840,290.72 |
| Impairment losses of assets | –25,811,952.34 | 4,558,381.97 |
| Loss on credit impairment | –764,202,894.93 | –719,592,459.50 |
| Gains from disposal of assets | 3,223,194.73 | 8,357,501.07 |
| **Operating profits** | **2,394,384,388.01** | **2,331,008,439.61** |
| Add: Non-operating income | 25,362,943.19 | 26,840,297.08 |
| Less: Non-operating expenses | 21,515,505.68 | 23,853,764.85 |
| **Total profits** | **2,398,231,825.52** | **2,333,994,971.84** |
| Less: Income tax expenses | 652,202,444.81 | 649,337,212.22 |
| **Net profits** | **1,746,029,380.71** | **1,684,657,759.62** |
| Including: Net profits of the absorbed party before business combination under common control | – | – |
| Net profits attributable to the owners of the parent company | 1,419,915,264.20 | 1,344,321,174.24 |
| *Gains and losses of minority interests | 326,114,116.51 | 340,336,585.38 |
| **Other comprehensive income, net of tax** | **–720,873.79** | **152,974.12** |
| **Total comprehensive income** | **1,745,308,506.92** | **1,684,810,733.74** |

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED**
**CONSOLIDATED STATEMENT OF CASH FLOWS**
**JANUARY TO SEPTEMBER 2026**

**Unit: RMB**

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **I. Cash flows from operating activities:** | | |
| Cash received from the sales of goods and the rendering of services | 172,901,640,519.39 | 166,991,549,882.16 |
| Refund of taxes and levies | 328,435.61 | 2,177,080.96 |
| Cash received relating to other operating activities | 9,599,933,529.32 | 9,550,425,874.82 |
| **Sub-total of cash inflows from operating activities** | **182,501,902,484.32** | **176,544,152,837.94** |
| Cash paid for goods purchased and services received | 163,929,781,810.78 | 158,924,725,028.60 |
| Cash paid to and for employees | 3,734,483,532.01 | 3,695,510,015.75 |
| Payments of all types of taxes | 2,975,572,908.33 | 2,888,933,738.47 |
| Cash payments relating to other operating activities | 11,534,092,484.91 | 11,071,231,275.61 |
| **Sub-total of cash outflows from operating activities** | **182,173,930,736.03** | **176,580,400,058.43** |
| **Net cash flow from operating activities** | **327,971,748.29** | **–36,247,220.49** |
| **II. Cash Flow From Investing Activities:** | | |
| Cash received from investment recovery | 90,758,297.04 | – |
| Cash received from returns on investments | 21,739,177.09 | 27,738,246.89 |
| Net cash received from disposals of fixed assets, intangible assets and other long-term assets | 13,170,340.69 | 6,075,321.61 |
| Net cash received from disposals of subsidiaries and other operating units | – | 21,548,828.12 |
| Cash received relating to other investing activities | 52,947.94 | 70,321.11 |
| **Sub-total of cash inflows from investing activities** | **125,720,762.76** | **55,432,717.73** |
| Cash paid to acquire fixed assets, intangible assets and other long-term assets | 474,796,111.03 | 451,444,822.56 |
| Cash paid for investments | 95,000,000.00 | – |
| Net cash paid for acquisition of subsidiaries and other operational units | 5,400,000.00 | 11,887,769.50 |
| Cash payments relating to other investing activities | 781,389.51 | – |
| **Sub-total of cash outflows from investing activities** | **575,977,500.54** | **463,332,592.06** |
| **Net cash flow from investing activities** | **–450,256,737.78** | **–407,899,874.33** |

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **III. Cash flow from financing activities:** | | |
| Cash received from capital contribution | 1,000,000.00 | 31,100,000.00 |
| Cash received from borrowings | 40,126,719,867.94 | 42,163,203,525.21 |
| Cash received from issuance of bonds | 5,200,000,000.00 | 5,000,000,000.00 |
| Cash received relating to other financing activities | 2,971,402,888.87 | 2,925,989,320.98 |
| **Sub-total of cash inflows from financing activities** | **48,299,122,756.81** | **50,120,292,846.19** |
| Cash payments for debts settlement | 44,446,900,579.22 | 43,861,399,409.13 |
| Cash payments for distribution of dividends, profits, or interest expenses | 2,230,126,415.64 | 2,289,249,520.12 |
| Cash payments relating to other financing activities | 3,396,068,322.14 | 4,480,373,215.02 |
| **Sub-total of cash outflows from financing activities** | **50,073,095,317.00** | **50,631,022,144.27** |
| **Net cash flow from financing activities** | **–1,773,972,560.19** | **–510,729,298.08** |
| **IV. Effect of foreign exchange rate changes on cash and cash equivalents** | **–1,773,972,560.19** | **–510,729,298.08** |
| **V. Net increase in cash and cash equivalents** | **–1,896,257,549.68** | **–954,876,392.90** |
| Add: Opening balance of cash and cash equivalent | 3,951,319,741.63 | 2,940,907,528.27 |
| **VI. Closing balance of cash and cash equivalents** | **2,055,062,191.95** | **1,986,031,135.37** |

# CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED
# BALANCE SHEET
# SEPTEMBER 2026

**Unit: RMB**

| Item | 30 September 2026 | 31 December 2025 | Item | 30 September 2026 | 31 December 2025 |
|---|---|---|---|---|---|
| **Current assets:** | | | **Current liabilities:** | | |
| Monetary fund | 1,818,999,661.27 | 3,782,306,964.46 | Short-term borrowings | 1,677,792,939.69 | 484,541,139.63 |
| Accounts receivable | 7,206,439,970.86 | 5,296,570,695.20 | Notes payable | 1,430,557,808.40 | 1,581,273,979.00 |
| Financing receivables | 259,066,111.95 | 145,528,497.76 | Accounts payable | 4,072,320,375.14 | 2,697,870,457.89 |
| Prepayment | 155,644,867.21 | 221,125,847.99 | Contract liabilities | 51,699,573.50 | 14,864,501.34 |
| Other receivables | 12,728,187,772.61 | 11,337,641,504.90 | Staff remuneration payable | 321,830,440.06 | 277,989,878.62 |
| Inventory | 1,794,680,746.87 | 1,719,653,237.84 | Taxation payable | 21,904,608.32 | 17,016,034.61 |
| Contract assets | 3,467,825.70 | 7,334,667.58 | Other payables | 10,539,385,410.38 | 13,754,306,926.13 |
| Non-current assets due within one year | 1,102,266,666.69 | – | Non-current liabilities due within one year | 4,125,237,701.84 | 3,696,695,892.62 |
| Other current assets | 223,237,384.57 | 236,133,555.18 | Other current liabilities | – | 1,409,734.07 |
| **Total current assets** | **25,291,991,007.73** | **22,746,294,970.91** | **Total current liabilities** | **22,240,728,857.33** | **22,525,968,543.91** |
| **Non-current assets:** | | | **Non-current liabilities:** | | |
| Long-term receivables | 10,690,821,064.35 | 11,886,290,354.28 | Long-term borrowings | 970,000,000.00 | 3,335,000,000.00 |
| Long-term equity investments | 30,062,183,272.59 | 29,839,529,534.51 | Bonds payable | 11,998,931,679.52 | 7,996,868,303.42 |
| Investment properties | 4,090,575.11 | 4,420,658.48 | Long-term payables | 91,250,872.72 | 85,954,204.72 |
| Other non-current financial assets | 7,416,070.93 | 7,416,070.93 | Long-term employee remuneration payable | 85,308,098.51 | 84,910,684.26 |
| Fixed assets | 126,273,602.96 | 142,478,781.11 | Deferred income tax liabilities | 10,476,457.11 | 138,293.50 |
| Right-of-use assets | 44,522,879.58 | 41,905,828.39 | Lease liabilities | 23,996,433.10 | 22,605,577.45 |
| Construction in progress | 5,352,969.83 | 9,322,308.51 | **Total non-current liabilities** | **13,179,963,540.96** | **11,525,477,063.35** |
| Intangible assets | 55,858,654.90 | 55,664,535.26 | **Total liabilities** | **35,420,692,398.29** | **34,051,445,607.26** |
| Goodwill | – | – | **Owners' equity (or shareholders' equity):** | | |
| Long-term deferred expenses | 2,558,338.03 | 3,636,245.93 | Paid-in capital (equity) | 19,646,531,357.61 | 19,646,531,357.61 |
| Deferred income tax assets | 10,492,909.99 | 154,746.38 | Other equity instruments | 6,000,000,000.00 | 6,000,000,000.00 |
| Other non-current assets | 1,447,698.00 | 1,880,370.82 | Capital surplus | 3,748,322,739.70 | 3,728,711,431.50 |
| **Total non-current assets** | **41,011,018,036.27** | **41,992,699,434.60** | Other comprehensive income | –19,136,066.79 | –18,415,193.00 |
| | | | Surplus reserves | 1,280,741,073.49 | 1,280,741,073.49 |
| | | | Undistributed profits | 225,857,541.70 | 49,980,128.65 |
| | | | **Total equity attributable to owners of the parent company** | **30,882,316,645.71** | **30,687,548,798.25** |
| | | | **Total owners' equity** | **30,882,316,645.71** | **30,687,548,798.25** |
| **Total assets** | **66,303,009,044.00** | **64,738,994,405.51** | **Total liabilities and owners' equity** | **66,303,009,044.00** | **64,738,994,405.51** |

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED**
**STATEMENT OF PROFIT OR LOSS**
**JANUARY TO SEPTEMBER 2026**

**Unit: RMB**

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **Operating revenue** | **14,786,826,035.54** | **13,673,703,742.95** |
| **Less: Operating costs** | **14,059,899,469.09** | **12,955,434,466.37** |
| Tax and surcharge | 21,233,534.59 | 23,265,828.56 |
| Selling expenses | 335,071,203.27 | 324,828,806.77 |
| Management expenses | 453,771,503.73 | 379,564,041.74 |
| Research and development expenses | 12,152,525.62 | 33,939,388.47 |
| Finance costs | –148,951,511.90 | –62,409,775.25 |
| Including: Interest expenses | 301,729,729.04 | 317,946,662.57 |
| Interest income | 452,555,131.96 | 382,538,734.44 |
| Add: Other revenue | 718,910.10 | 1,348,016.86 |
| Gain from investment | 1,218,955,489.12 | 308,351,113.08 |
| Including: Gains from investment in associates and joint ventures | 104,356,784.15 | 108,490,921.79 |
| Gains from changes in fair values | – | –474,050.45 |
| Impairment losses of assets | –814,471.88 | –126,556.42 |
| Loss on credit impairment | –10,488,474.89 | –6,333,044.47 |
| Gains from disposal of assets | 68,391.40 | 15,677.05 |
| **Operating profits** | **1,262,089,154.99** | **321,862,141.94** |
| Add: Non-operating income | 275,930.84 | 7,351,328.84 |
| Less: Non-operating expenses | 63,950.31 | 1,882,208.86 |
| **Total profits** | **1,262,301,135.52** | **327,331,261.92** |
| Less: Income tax expenses | – | – |
| **Net profits** | **1,262,301,135.52** | **327,331,261.92** |
| Including: Net profits of the absorbed party before business combination under common control | – | – |
| Net profits attributable to the owners of the parent company | 1,262,301,135.52 | 327,331,261.92 |
| **Other comprehensive income, net of tax** | **–720,873.79** | **152,974.12** |
| **Total comprehensive income** | **1,261,580,261.73** | **327,484,236.04** |

**CHINA RESOURCES PHARMACEUTICAL COMMERCIAL GROUP COMPANY LIMITED**
**STATEMENT OF CASH FLOWS**
**JANUARY TO SEPTEMBER 2026**

**Unit: RMB**

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **I. Cash flows from operating activities:** | | |
| Cash received from the sales of goods and the rendering of services | 14,335,979,566.60 | 14,003,945,949.94 |
| Refund of taxes and levies | – | – |
| Cash received relating to other operating activities | 23,923,786.46 | 26,907,690.26 |
| **Sub-total of cash inflows from operating activities** | **14,359,903,353.06** | **14,030,853,640.20** |
| Cash paid for goods purchased and services received | 13,105,538,736.52 | 12,973,669,752.58 |
| Cash paid to and for employees | 485,486,007.47 | 509,534,058.71 |
| Payments of all types of taxes | 145,686,822.67 | 142,461,464.94 |
| Cash payments relating to other operating activities | 247,715,515.35 | 249,474,055.67 |
| **Sub-total of cash outflows from operating activities** | **13,984,427,082.01** | **13,875,139,331.90** |
| **Net cash flow from operating activities** | **375,476,271.05** | **155,714,308.30** |
| **II. Cash Flow From Investing Activities:** | | |
| Cash received from investment recovery | 6,748,234,230.82 | 12,507,411,020.00 |
| Cash received from returns on investments | 814,616,566.34 | 847,770,066.64 |
| Net cash received from disposals of fixed assets, intangible assets and other long-term assets | 182,876.20 | 50,028.29 |
| Net cash received from disposals of subsidiaries and other operating units | – | – |
| Cash received relating to other investing activities | – | – |
| **Sub-total of cash inflows from investing activities** | **7,563,033,673.36** | **13,355,231,114.93** |
| Cash paid to acquire fixed assets, intangible assets and other long-term assets | 16,496,055.18 | 14,469,598.73 |
| Cash paid for investments | 7,083,930,000.00 | 16,012,465,566.62 |
| Net cash paid for acquisition of subsidiaries and other operational units | – | – |
| Cash payments relating to other investing activities | – | – |
| **Sub-total of cash outflows from investing activities** | **7,100,426,055.18** | **16,026,935,165.35** |
| **Net cash flow from investing activities** | **462,607,618.18** | **–2,671,704,050.42** |

| Item | January–September 2026 | January–September 2025 |
|---|---|---|
| **III. Cash flow from financing activities:** | | |
| Cash received from capital contribution | – | – |
| Cash received from borrowings | 3,700,000,000.00 | 2,495,000,000.00 |
| Cash received from issuance of bonds | 5,200,000,000.00 | 5,000,000,000.00 |
| Cash received relating to other financing activities | 1,992,870,048.62 | 943,463,171.22 |
| **Sub-total of cash inflows from financing activities** | **10,892,870,048.62** | **8,438,463,171.22** |
| Cash payments for debts settlement | 6,787,512,492.44 | 980,682,594.38 |
| Cash payments for distribution of dividends, profits, or interest expenses | 1,432,625,826.52 | 1,310,316,283.01 |
| Cash payments relating to other financing activities | 5,474,122,670.00 | 4,616,999,283.49 |
| **Sub-total of cash outflows from financing activities** | **13,694,260,988.96** | **6,907,998,160.88** |
| **Net cash flow from financing activities** | **–2,801,390,940.34** | **1,530,465,010.34** |
| **IV. Effect of foreign exchange rate changes on cash and cash equivalents** | **–** | **–** |
| **V. Net increase in cash and cash equivalents** | **–1,963,307,051.11** | **–985,524,731.78** |
| Add: Opening balance of cash and cash equivalent | 3,782,306,604.46 | 2,613,119,787.23 |
| **VI. Closing balance of cash and cash equivalents** | **1,818,999,553.35** | **1,627,595,055.45** |